Xanthus' Symadex Performs Well in MS Study
Posted on: Tuesday, 14 February 2006, 12:00 CST
Xanthus Life Sciences has reported encouraging data from a study in which Symadex permitted remyelination by prevention of inflammatory cell infiltration in a multiple sclerosis animal model.
Symadex was found to produce remyelination (repair of damaged myelin) in the study even after 40 days of inflammatory insult by preventing the infiltration of autoreactive cells into the central nervous system. Treatment proved to be effective in both the acute and chronic forms of the disease.
"The early results from this study showed that the animals in the study, which were paralyzed due to neurological impairment, were able to recover and regain their mobility after treatment with Symadex," commented Dr Stephen Karlik, professor of diagnostic radiology at the University of Western Ontario.
Symadex (formerly known as C-1311) is a next-generation investigational drug that has shown a potentially novel, targeted mechanism of action in studies of cancer and autoimmune disease.
The drug candidate is currently being evaluated in phase II trials in oncology, and Xanthus expects the new MS study data to support a move towards human testing in the MS indication.
Source: Datamonitor
Related Articles
- Xanthus' Symadex Demonstrates Ability to Increase Spinal Cord Remyelination in Multiple Sclerosis Model
- Xanthus Presents Preclinical Data Demonstrating Potent Symadex Activity in Leukemia Cells
- Xanthus Presents In Vitro Data Demonstrating That Symadex Is a Potent and Selective Inhibitor of FLT3
- Xanthus' Symadex OK in Phase 1 Trial
- Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting
- Xanthus Initiates Phase 2 Clinical Trial With Symadex in Patients With Metastatic Colorectal Cancer
- Xanthus Initiates Phase 2 Clinical Trial With Symadex in Women With Metastatic Breast Cancer
- Impact of a High School Graduation Examination on Social Studies Teachers' Instructional Practices
- Xanthus Initiates a Phase 2 Study Of Xanafide in Combination With Ara-C for Treatment Of Secondary AML
 |
 |
User Comments (0)
RSS Feeds